BMI1 and Miyoshi myopathy: Taken together with our findings that BMI1 upregulation drives MM-MΦ’s pro-myeloma functions, our work provided evidences and molecular basis that the BMI1 inhibitor targeted tumor-promoting MM-MΦs in the MM microenvironment.